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Each year in England ~230 babies born at <32 weeks gestation develop severe necrotising enterocolitis 
(NEC), with approximately half of them dying.[1] Successive meta-analyses indicate that dual-strain 
probiotics ˗  specifically the combination of Bifidobacterium and Lactobacillus species ˗  significantly reduce 
the incidence of NEC in very low birth weight infants (VLBWI; <1500g) and halve mortality.[2-4]  A 2014 
national UK survey[4] done prior to publication of the Probiotic in Preterm babies Study (PiPS) trial,[5] 
showed that only 12% (7/58) UK tertiary NICUs were using probiotics, while more than half were awaiting 
the PiPS results. We aimed to determine if the prevalence of probiotic use has changed since publication of 
the PiPS study in 2015.  
During June-July 2018, we telephone surveyed all 58 UK tertiary-level NICUs.  We asked a senior 
member of the medical team (registrar/ANNP/consultant) if their NICU was currently using probiotics for 
prophylaxis of NEC. 
All 58 (100%) units responded. Only 10 (17%) currently used probiotics routinely, all used multi-strain 
formulations (Lactobacillus acidophilus plus ≥1 Bifidobacterium): n=7 Labinic Drops® (Biofloratech, 
UK); n=3 Infloran® (Desma Healthcare, Switzerland). There has been no significant increase in probiotics 
use in UK NICUs since 2014 (10/58 versus 7/58, p-value =0.6, χ2). 
Notwithstanding the strong evidence of benefit from using dual-strain probiotics shown by meta-
analyses,[2,3] the large PiPS trial which used a single-strain Bifidobacterium breve and had a null result 
has likely influenced the wider adoption of probiotics in the UK. If current meta-analyses are misleading 
then several hundred high-risk babies receive probiotics annually in the UK for no benefit, albeit at a small 
monetary cost to the NHS but negligible risk otherwise. However, if the meta-analyses are not misleading 
then thousands of high-risk UK babies (and their families) are being denied an important treatment that, 
with a risk reduction of ~0.5[2,3], would be preventing severe NEC in at least 100 babies born in England 
per year and saving the lives of at least 50 annually.  
How to negotiate the impasse? Is a new large RCT of dual-strain prophylaxis required to finally 
adjudicate? It seems unlikely that such a trial will be done. Based on the 3% incidence of severe NEC in 
babies <32 weeks gestation,[1] to show a halving of severe NEC incidence with a prophylactic dual-strain 
Lactobacillus-Bifidobacterium probiotic combination, a theoretical future RCT would require ~n=3500 
babies.  
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Meanwhile there is mounting supportive evidence from many countries that have already introduced 
dual-strain probiotics. In Germany most centres routinely offer probiotics below 32 weeks’ gestation and 
70% of German VLBWI receive dual-strain probiotics,[6] a stark contrast to UK practice. A large 
observational time-series analysis comparing n=5818 dual-strain probiotic treated (Infloran®) versus 
n=5072 untreated VLBWI from 44 German NICUs showed that probiotics were associated with markedly 
reduced NEC incidence (hazard ratio 0.48, 95% CI: 0.38-0.62), reduced overall mortality (hazard ratio 0.60, 
95% CI: 0.44-0.83) and post-NEC mortality (hazard ratio 0.51, 95% CI: 0.26-0.99).[7] These impressive 
findings mirror those of the meta-analyses.  
One valid conclusion from the cumulated mass of current evidence is that widespread UK adoption of 
dual-strain probiotics for VLBWI would save the lives of >50 babies each year, not to mention the huge 
morbidity/cost burden to the NHS and families of surviving NEC babies. With such high stakes, a NICE 
(National Institute for Health and Care Excellence) guideline making evidence-based recommendations on 
the clinical and cost effectiveness of probiotics to prevent NEC in preterm infants is urgently needed and 
would be universally welcomed. 
Reliable up-to-date data on NEC incidence are needed from all UK NICUs, but there is a particular onus 
on probiotics-using centres to present their data. NEC rates may possibly have reduced generally in recent 
years in line with increased breast-milk feeding. However, until a standardised, strict NEC working 
definition is agreed, any comparisons may remain confounded. 
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